J
Joachim von Pawel
Researcher at University of Texas MD Anderson Cancer Center
Publications - 144
Citations - 27028
Joachim von Pawel is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Lung cancer & Chemotherapy. The author has an hindex of 52, co-authored 142 publications receiving 25012 citations.
Papers
More filters
Journal ArticleDOI
P3-116: Phase II study of DMXAA (AS1404) 1800 mg/m2 combined with carboplatin and paclitaxel in non-small cell lung cancer
Journal ArticleDOI
Diagnostische Bedeutung zirkulierender DNA- Fragmente in der Onkologie. Diagnostic importance of circulating DNA fragments in oncology
TL;DR: The physiological and pathophysiological background of the arrangement of DNA as nucleosomes and of its release into circulation is shown, and the diagnostic relevance of qualitative and quantitative changes in circulating DNA for screening, differential diagnosis, prognosis, monitoring of systemic therapies, early prediction of therapy response and detection of recurrence in malignant diseases is reviewed.
Journal ArticleDOI
A1-06: Randomized multicenter german trial of surgery plus radiotherapy versus tri-modality treatment of operable stage IIIA NSCLC - long-term follow-up results
Wilfried Eberhardt,Sönke Korfee,Christoph Pöttgen,Horst Wagner,Thomas Gauler,Bernward Passlick,Georgios Stamatis,Joachim von Pawel,Volker Budach,Hansjochen Wilke,Martin Stuschke +10 more
Journal ArticleDOI
Treatment of advanced recurrent NSCLC with daily oral vinorelbine: A phase I trial.
Amanda Tufman,Astrid Borgmeier,Sylvia Guetz,Joachim von Pawel,Achim Rittmeyer,Rudolf M. Huber +5 more
TL;DR: A phase I dose finding study in which a regimen of daily oral vinorelbine was evaluated in pretreated patients with advanced NSCLC and the primary end point was the identification of the maximum tolerated dose.
Proceedings ArticleDOI
Abstract 2376: Improved progression-free survival (PFS) in patients with short tumor telomere length: Subgroup analysis from a randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced NSCLC .
Alberto Chiappori,Ekaterina Bassett,Bart Burington,Tatjana Kolevska,David R. Spigel,Steven Hager,Mark U. Rarick,Shirish M. Gadgeel,Normand Blais,Joachim von Pawel,Lowell L. Hart,Hui Wang,Kevin Eng,Martin Reck,Joan H. Schiller +14 more
TL;DR: It is suggested that imetelstat given as maintenance therapy prolongs progression-free survival (PFS) in pts with advanced NSCLC whose tumors have short telomeres as measured by qPCR, consistent with the hypothesis that clinical benefit from telomerase inhibition is greater in patients with tumors possessing shortTelomeres.